aTyr Pharma logo

aTyr PharmaNASDAQ: LIFE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2015

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A
$104.21 M
-69%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-85%vs. 3y high
45%vs. sector
177.22
-27%vs. 3y high
96%vs. sector

Price

regular market | Fri, 05 Jul 2024 13:30:00 GMT
$1.51-$0.03(-1.95%)

Dividend

No data over the past 3 years
$235.00 K$20.00 K
$235.00 K-$15.49 M

Analysts recommendations

Institutional Ownership

LIFE Latest News

GLOBE LIFE ALERT: Bragar Eagel & Squire, P.C. is Investigating Globe Life, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com03 July 2024 Sentiment: -

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Globe Life, Inc. (NYSE: GL) on behalf of long-term stockholders following a class action complaint that was filed against Globe Life on April 30, 2024 with a Class Period from May 8, 2019 to April 10, 2024. Our investigation concerns whether the board of directors of Globe Life have breached their fiduciary duties to the company.

GLOBE LIFE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
accesswire.com27 June 2024 Sentiment: -

NEW ORLEANS, LA / ACCESSWIRE / June 27, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE:GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period").

GLOBE LIFE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
globenewswire.com26 June 2024 Sentiment: -

NEW ORLEANS, June 26, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the “Class Period”). Long term holders of GL are also encouraged to contact the firm. This action is pending in the United States District Court for the Eastern District of Texas.

GLOBE LIFE Inc. Sued for Securities Law Violations - Contact The Schall Law Firm Before July 12, 2024 to Discuss Your Rights - GL
prnewswire.com26 June 2024 Sentiment: -

LOS ANGELES , June 26, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Globe Life Inc. ("Globe Life" or "the Company") (NYSE: GL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2019 and April 10, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 1, 2024.

GLOBE LIFE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
accesswire.com24 June 2024 Sentiment: -

NEW ORLEANS, LA / ACCESSWIRE / June 24, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE:GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period").

Neotech Metals Announces LIFE Financing
newsfilecorp.com24 June 2024 Sentiment: -

Vancouver, British Columbia--(Newsfile Corp. - June 24, 2024) - Neotech Metals Corp. (CSE: NTMC) (OTC Pink: NTMFF) (FSE: V690) ("Neotech" or the "Company"), is pleased to announce that it intends to complete a non-brokered private placement LIFE financing (the "Offering") for total proceeds of a minimum of $1,500,000 and up to a maximum of $2,500,000, consisting of a minimum of 6,000,000 units of the Company (the "Units") and up to a maximum of 10,000,000 Units at a price of $0.25 per Unit. Each Unit will be comprised of one common share in the authorized share structure of the Company (each, a "Common Share") and one Common Share purchase warrant (a "Warrant") of the Company.

GLOBE LIFE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
prnewswire.com21 June 2024 Sentiment: -

NEW ORLEANS , June 21, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period").

GLOBE LIFE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
accesswire.com20 June 2024 Sentiment: -

NEW ORLEANS, LA / ACCESSWIRE / June 20, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE:GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period").

GLOBE LIFE, INC. INVESTORS: Pending Lead Plaintiff Deadline in GL Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
globenewswire.com20 June 2024 Sentiment: -

SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Globe Life, Inc. f/k/a Torchmark Corporation (NYSE: GL) common stock between May 8, 2019 and April 10, 2024. Globe Life is an insurance company that offers a wide range of insurance products, including life insurance, mortgage protections, and supplemental health insurance.

GLOBE LIFE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Globe Life Inc. - GL
globenewswire.com19 June 2024 Sentiment: -

NEW ORLEANS, June 19, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the “Class Period”). Long term holders of GL are also encouraged to contact the firm. This action is pending in the United States District Court for the Eastern District of Texas.

  • 1(current)
  • 2

What type of business is aTyr Pharma?

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

What sector is aTyr Pharma in?

aTyr Pharma is in the Healthcare sector

What industry is aTyr Pharma in?

aTyr Pharma is in the Biotechnology industry

What country is aTyr Pharma from?

aTyr Pharma is headquartered in United States

When did aTyr Pharma go public?

aTyr Pharma initial public offering (IPO) was on 07 May 2015

What is aTyr Pharma website?

https://www.atyrpharma.com

Is aTyr Pharma in the S&P 500?

No, aTyr Pharma is not included in the S&P 500 index

Is aTyr Pharma in the NASDAQ 100?

No, aTyr Pharma is not included in the NASDAQ 100 index

Is aTyr Pharma in the Dow Jones?

No, aTyr Pharma is not included in the Dow Jones index

When does aTyr Pharma report earnings?

The next expected earnings date for aTyr Pharma is 09 August 2024